Search Results

Corporate

March 30, 2017

Johnson & Johnson Innovation Launches Advancing the Safe Use of Healthcare Products QuickFire Challenge

Challenge awards up to $200,000 to novel solutions that advance safety by informing patients and consumers, simulating surgical procedures or ensuring proper storage and use of prescription, over-the-counter and cosmetic products

Innovative Medicine

March 30, 2017

Janssen Discontinues Development of Flubendazole Formulation to Treat Onchocerciasis

Research supported Johnson & Johnson’s commitment to the 2012 London Declaration on Neglected Tropical Diseases and yielded important findings

Global health equity

March 23, 2017

Johnson & Johnson Innovation launches Singapore QuickFire Challenge Competition in collaboration with ETPL and SMART to accelerate solutions for diabetes and other metabolic diseases

Innovative Medicine

March 18, 2017

New Phase 3 Study Finds XARELTO® to Be Superior to Aspirin for Long-Term Prevention of Recurrent Blood Clots Without Observing any Significant Increase in Major Bleeding in Patients with Venous Thromboembolism

Global health equity

March 14, 2017

Johnson & Johnson Reports that Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination in Phase 1 Study

Global health equity

March 14, 2017

Johnson & Johnson Names Winners of First Africa Innovation Challenge

Competition Part of Company’s Eighty-Five Year Commitment to Supporting Entrepreneurs, Science Education Opportunities, and Health Systems Across the Continent

Innovative Medicine

March 6, 2017

Late-Breaking Results from XARELTO® (rivaroxaban) EINSTEIN CHOICE and GEMINI-ACS-1 Studies Among Research Accepted for Presentation at the American College of Cardiology 66th Annual Scientific Session

Innovative Medicine

March 3, 2017

New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis

Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA® in the Treatment of Moderate to Severe Plaque Psoriasis

Innovative Medicine

February 24, 2017

DARZALEX®▼ (daratumumab) Receives Positive CHMP Opinion for the Treatment of Multiple Myeloma in Patients who have Received At Least One Prior Therapy

Janssen’s first-in-class CD38-directed monoclonal antibody now recommended for approval earlier in the treatment pathway in combination with two standard of care regimens

Innovative Medicine

February 23, 2017

Johnson & Johnson Announces Further Patent and Trademark Office Action Related to REMICADE®

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine